medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2023, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2023; 21 (2)

Verrucous syndrome: differential diagnosis

Soto SLG, Armendáriz BY, Hernández NVA, Lupercio MSM, Medina VNA, Sáenz RAV, Arenas GR

Language: Spanish
References: 65
Page: 173-185
PDF size: 257.25 Kb.


ABSTRACT

Dermatologists observe in daily practice a condition known as “verrucous syndrome”. This can be characterized as verrucous nodules or tumors covered by verrucous or vegetating plaques, which may have scales and/or crusts. Diagnosing this syndrome can be challenging due to the numerous potential causes. Therefore, this article presents a concise and current overview of the most significant diseases, as well as a proposed algorithm to improve an accurate diagnosis.


REFERENCES

  1. Saul A, Lecciones de dermatología, 16ª ed., México, McGrawHill Interamericana, 2018.

  2. Costa-Llanos F, Martínez C y Azulay L, plect: enfermedadestropicales de manifestación verrucosa, Rev Chil Dermatol 2018; 34(3):312-24.

  3. Brito AC, Oliveira CMM, Unger DA y Bittencourt MJS, Cutaneoustuberculosis: epidemiological, clinical, diagnostic andtherapeutic update, An Bras Dermatol 2022; 97(2):129-44. doi:10.1016/j.abd.2021.07.004. Epub, 4 de enero de 2022. pmid:34996655; pmcid: pmc: 9073256.

  4. Pinto-Almazán R, Sandoval-Navarro KA, Damián-Magaña EJ,Arenas R, Fuentes-Venado C, Zárate-Segura PB, Martínez-HerreraE y Rodríguez-Cerdeira C, Relationship of sporotrichosisand infected patients with hiv-aids: an actual systematic review,J. Fungi 2023; 9:396. Disponible en: https://doi.org/10.3390/jof9040396.

  5. Hernández-Castro R, Pinto-Almazán R, Arenas R, Sánchez-CárdenasCD, Espinosa-Hernández VM, Sierra-Maeda KY, Conde-Cuevas E, Juárez-Durán ER, Xicohtencatl-Cortés J, Carrillo-Casas EM, Steven-Velásquez J, Martínez-Herrera E yRodríguez-Cerdeira C, Epidemiology of clinical sporotrichosisin the Americas in the last ten years, J. Fungi (Basilea) 2022;8(6):588. doi: 10.3390/jof8060588. pmid: 35736071; pmcid:pmc: 9224952.

  6. Mayorga-Rodríguez J, Mayorga-Garibaldi JL, Muñoz-Estrada VFy De León Ramírez RM, Esporotricosis: serie de 1134 casos enuna zona endémica de México, Med Corte Ibero Lat Am 2019;47:24-8.

  7. Bonifaz-Trujillo A, Micología médica básica, 6ª ed., México, Mc-Graw Hill, 2020.

  8. Liu F, Liu Y, Yuan N, Zhang X, Cao M, Dong J y Zhang J, Fixedcutaneous sporotrichosis due to Sporothrix globose, Clin CosmetInvestig Dermatol 2021; 14:91-6. doi: 10.2147/ccid.s288259.pmid: 33531824; pmcid: pmc: 7846868.

  9. Gu A, Zhang X, Ma F, Nie Z, Sybren de Hoog G y Zhang Y, Fixedcutaneous sporotrichosis in a patient with numerous fungalelements, Med Mycol Case Rep 2020; 29:32-4. doi: 10.1016/j.mmcr.2020.06.001. pmid: 32676277; pmcid: pmc: 7352048.

  10. Martínez-Herrera E, Arenas R, Hernández-Castro R, Frías-de-León MG y Rodríguez-Cerdeira C, Uncommon clinical presentationsof sporotrichosis: a two-case report, Pathogens 2021;10(10):1249. doi: 10.3390/pathogens10101249. pmid: 34684198;pmcid: pmc: 8541424.

  11. Arrillaga-Moncrieff I, Capilla J, Fernández AM et al., Diferenciasen la patogenicidad del complejo de especies Sporothrix en unmodelo animal, Patología Rev Latinoam 2010; 48(2);82-7.

  12. Arenas R, Sánchez-Cárdenas CD, Ramírez-Hobak L, Ruíz ArriagaLF y Vega Memije ME, Sporotrichosis: from koh to molecular biology,J Fungi (Basilea) 2018; 4(2):62. doi: 10.3390/jof4020062.pmid: 29882883; pmcid: pmc: 6023365.

  13. Hirsh B y Johnson W, Patología de las enfermedades granulomatosas;granulomas inflamatorios mixtos, Int J Dermatol1984; 23:585-97. doi: 10.1111/j.1365-4362.1984.tb05695.x.

  14. Rudramurthy SM y Chakrabarti A, Sporotrichosis: update on diagnostictechniques, Curr Fungal Infect Rep 2017; 11:134-40.Disponible en: https://doi.org/10.1007/s12281-017-0283-8.

  15. Rodrigues AM, Gonçalves SS, De Carvalho JA, Borba-Santos LP,Rozental S y Camargo ZP, Current progress on epidemiology, diagnosis,and treatment of sporotrichosis and their future trends,J Fungi (Basilea) 2022; 8(8):776. doi: 10.3390/jof8080776. pmid:35893145; pmcid: pmc: 9331723.

  16. Brito AC y Bittencourt MJS, Chromoblastomycosis: an etiological,epidemiological, clinical, diagnostic, and treatment update,An Bras Dermatol 2018; 93(4):495-506.

  17. Seas C y Legua P, Mycetoma, chromoblastomycosis and otherdeep fungal infections: diagnostic and treatment approach, CurrOpin Infect Dis 2022; 35(5):379-83.

  18. Queiroz-Telles F, De Hoog S, Santos DW, Salgado CG, VicenteVA, Bonifaz A, Roilides E, Xi L, Azevedo CM, Da Silva MB, PanaZD, Colombo AL y Walsh TJ, Chromoblastomycosis, Clin MicrobiolRev 2017; 30(1):233-76.

  19. Koehler A, Heidrich D, Pagani DM, Corbellini VA y ScrofernekerML, Melanin and chromoblastomycosis agents: characterization,functions, and relation with antifungals, J Basic Microbiol 2021;61(3):203-11.

  20. Guevara A, Siqueira NP, Nery AF, Cavalcante LR, Hagen F y Hahn RC,Chromoblastomycosis in Latin America and the Caribbean: epidemiologyover the past 50 years, Med Mycol 2021;60(1):myab062.

  21. Romero-Navarrete M, Arenas R, Muñoz-Estrada VF, Atoche-DiéguezCE, Mayorga J, Bonifaz A, Moraila-Moya GA, Paredes-SolísS y Castillo-Solana A, Cromoblastomicosis en México: revisiónde 603 casos en siete décadas, dcmq 2014; 12(2):87-93.

  22. Borges JR, Ximenes BAS, Miranda FTG, Peres GBM, HayasakiIT, Ferro LCC, Ianhez M y García-Zapata MTA, Accuracy of directexamination and culture as compared to the anatomopathologicalexamination for the diagnosis of chromoblastomycosis: asystematic review, An Bras Dermatol 2022; 97(4):424-34.

  23. Giraldelli GA, Baka JLCS, Orofino-Costa R, Piñeiro-Maceira J,Barcaui E y Barcaui CB, In vivo reflectance confocal microscopy,dermoscopy, high-frequency ultrasonography, and histopathologyfeatures in a case of chromoblastomycosis, plos Negl TropDis 2022; 16(3):e0010226.

  24. Maubon D, Garnaud C, Ramarozatovo LS, Fahafahantsoa RR,Cornet M y Rasamoelina T, Molecular diagnosis of two majorimplantation mycoses: chromoblastomycosis and sporotrichosis,J Fungi (Basilea) 2022; 8(4):382.

  25. Bienvenu AL y Picot S. Mycetoma and chromoblastomycosis:perspective for diagnosis improvement using biomarkers, Molecules2020; 25(11):2594.

  26. Sousa IS, Mello TP, Pereira EP, Granato MQ, Alviano CS, SantosALS y Kneipp LF, Biofilm formation by chromoblastomycosisFungi Fonsecaea pedrosoi and Phialophora verrucosa:involvement with antifungal resistance, J Fungi (Basilea) 2022;8(9):963.

  27. Arenas R, Dermatología. Atlas, diagnóstico y tratamiento, 7ªed., México, McGraw Hill Interamericana, 2019.

  28. Crum NF, Coccidioidomycosis: a contemporary review, InfectDis Ther 2022; 11(2):713-42. doi: 10.1007/s40121-022-00606-y.Epub 1 de marzo de 2022. pmid: 35233706; pmcid: pmc:8887663.

  29. Johnson RH, Sharma R, Kuran R, Fong I y Heidari A, Coccidioidomycosis:a review, J Investig Med 2021; 69(2):316-23. doi:10.1136/jim-2020-001655. Errata en J Investig Med 2021;69(8):1486. pmid: 33495302; pmcid: pmc: 7848065.

  30. Reyna-Rodríguez IL, Ocampo-Candiani J y Chávez-Álvarez S, Primarycutaneous coccidioidomycosis: an update, Am J Clin Dermatol2020; 21(5):681-96. doi: 10.1007/s40257-020-00525-z.pmid: 32557380.

  31. Porte L, Valdivieso F, Wilmes D et al., Laboratory exposure tococcidioides: lessons learnt in a non-endemic country, J HospInf 2019; 102:461-4. Disponible en: https://doi-org.pbidi.unam.mx:2443/10.1016/j.jhin.2019.03.006.

  32. Basterreix KP, De los Ángeles Michelena M, Garritano MV, ArenaG, Maradeo R, Alves E et al., A propósito de un caso, 2016;66 (2): 53-57 Disponible en: http://www.archivosdermato.org.ar/wp-content/uploads/2019/10/53Basterreix-Paracoccidioidomicosis.pdf.

  33. Canteros CE, Paracoccidioidomicosis: crónica de una enfermedadolvidada, 2018; 78:180-4. Disponible en: https://www.medicinabuenosaires.com/PMID/29940544.pdf.

  34. Marques AS, Paracoccidioidomycosis, Clin Dermatol 2012; 30(6):610-5. doi: 10.1016/j.clindermatol.2012.01.006. pmid: 23068148.

  35. Hahn RC, Hagen F, Mendes RP, Burger E, Nery AF, Siqueira NP,Guevara A, Rodrigues AM y De Camargo ZP, Paracoccidioidomycosis:current status and future trends, Clin Microbiol Rev 2022;35(4):e0023321. doi: 10.1128/cmr.00233-21.

  36. Kaul S, Kaur I, Mehta S y Singal A, Cutaneous tuberculosis.Part i: Pathogenesis, classification, and clinical features, J AmAcad Dermatol 2022. doi: 10.1016/j.jaad.2021.12.063. pmid:35149149.

  37. Khadka P, Koirala S y Thapaliya J, Cutaneous tuberculosis: clinicopathologicarrays and diagnostic challenges, Dermatol ResPract 2018; 2018:7201973. doi: 10.1155/2018/7201973. pmid:30111996; pmcid: pmc: 6077618.

  38. Brito AC, Oliveira CMM, Unger DA y Bittencourt MJS, Cutaneoustuberculosis: epidemiological, clinical, diagnostic andtherapeutic update, An Bras Dermatol 2022; 97(2):129-44. doi:10.1016/j.abd.2021.07.004. Epub 4 de enero de 2022. pmid:34996655; pmcid: pmc: 9073256.

  39. Franco-Paredes C, Marcos LA, Henao-Martínez AF, Rodríguez-Morales AJ, Villamil-Gómez WE, Gotuzzo E y Bonifaz A, Cutaneousmycobacterial infections, Clin Microbiol Rev 2018; 32(1).doi: 10.1128/CMR.00069-18.

  40. Estrada-Moreno BE, Sánchez-Tadeo MT, Barrios-Pérez KV yGonzález-Angulo MN, Infección cutánea por micobacteriasatípicas del complejo M. abscessus, Dermatol Rev Mex 2022;66 (1):100-7.

  41. González-Santiago TM y Drage LA, Nontuberculous mycobacteria:skin and soft tissue infections, Dermatol Clin 2015;33(3):563-77. doi: 10.1016/j.det.2015.03.017.

  42. Mora AD, Giraldo S, Castillo DA y Ferro BE, Clinical behavior ofinfection and disease caused by non-tuberculous mycobacteriain Latin America: scoping review, Rev Peru Med Exp Salud Publica,2021; 38(2):318-25. doi: 10.17843/rpmesp.2021.382.6108.

  43. Veasey JV, Monteiro NAS, Lellis RF y Klautau GB, Cutaneousatypical mycobacteriosis with sporotrichoid clinical presentationcaused by automotive accident, An Bras Dermatol 2018;93(5):743-5. doi: 10.1590/abd1806-4841.20187586.

  44. Tuan J, Spichler-Moffarah A y Ogbuagu O, Mycobacterium marinum:nodular hand lesions after a fishing expedition, bmj CaseRep 2020; 13(12):e238835. doi: 10.1136/bcr-2020-238835.

  45. Que SKT, Zwald FO y Schmults CD, Cutaneous squamous cellcarcinoma, J Am Acad Dermatol 2018; 78(2):237-47.

  46. Halpern J, Harris S, Suárez V, Jeyaratnam R y Smith AG, Epitheliomacuniculatum: a case report, Foot Ankle Surg 2009;15(2):114-6.

  47. Torres-Guerrero DE, Perera Sid A, Conde Ortiz CE, Ilizaliturri Iy Vega Memije ME, Epitelioma cuniculatum: a propósito de uncaso, Rev Bioméd [Internet] 2020; 31(2).

  48. Aird I, Johnson HD, Lennox B y Stansfeld AG, Epithelioma cuniculatum,a variety of squamous carcinoma peculiar to the foot,Br J Surg 2005; 42(173):24550.

  49. García Bracamonte B, Carcinoma cuniculatum, un tumor infrecuentede localización habitualmente plantar, Más Dermatol2020; (31):4-11.

  50. Armendáriz BY, Guillén BAC, Pozos OLI et al., Epitelioma cuniculatum.A propósito de un caso, dcmq 2020; 18(2):104-7.

  51. Kao GF, Graham JH y Helwig EB, Carcinoma cuniculatum (verrucouscarcinoma of the skin): a clinicopathologic study of 46 caseswith ultrastructural observations, Cancer 1982; 49(11):2395-403.

  52. Méndez-Ojeda M, Corona Pérez-Cardona P, Herrera-Pérez M yPais-Brito J, Epitelioma cuniculatum de la planta del pie simulandouna infección, Acta Ortopédica Mex 2021; 35(2):211-4.

  53. Boettler MA, Gray AN, Brodsky MA, Shahwan KT y Carr DR,Mohs micrographic surgery for verrucous carcinoma: a reviewof the literature, Arch Dermatol Res 2022; 315(2):133-7.

  54. Abadías-Granado I, Diago A, Cerro PA, Palma-Ruiz AM y GilaberteY, Cutaneous and mucocutaneous leishmaniasis, ActasDermosifiliogr (Inglaterra) 2021; S0001-7310(21)00108-3. doi:10.1016/j.ad.2021.02.008. pmid: 33652011.

  55. Aronson NE y Joya CA, Cutaneous leishmaniasis: updates indiagnosis and management, Infect Dis Clin North Am 2019;33(1):101-117. doi: 10.1016/j.idc.2018.10.004. pmid: 30712756.

  56. Aronson N, Herwaldt BL, Libman M, Pearson R, López-VélezR, Weina P et al., Diagnosis and treatment of leishmaniasis:clinical practice guidelines by the Infectious Diseases Societyof America (idsa) and the American Society of Tropical Medicineand Hygiene (astmh), Am J Trop Med Hyg 2017; 96(1):24-45.

  57. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J yArenas R, Leishmaniasis: a review, F1000Research 2017; 6:750.doi: 10.12688/f1000research.11120.1. pmid: 28649370. pmc:5464238.

  58. Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B yBrooker S, Cutaneous leishmaniasis: authors’ reply, Lancet InfectDis 2008; 8(8):458-9

  59. Reveiz L, Maia-Elkhoury ANS, Nicholls RS, Romero GAS y YadonZE, Interventions for American cutaneous and mucocutaneousleishmaniasis: a systematic review update, plos One 2013;8(4):e61843.

  60. Vargas MF, Torres G, Arenas R et al., Leishmaniasis en México,Med Cutan Iber Lat Am 2011; 39(4):163-83.

  61. Burza S, Croft SL y Boelaert M, Leishmaniasis, The Lancet2018; 392(10151):951-70.

  62. De Brito RCF, Aguiar-Soares RD, De O Cardoso JM, De O Coura-Vital W, Roatt BM y Reis AB, Recent advances and new strategiesin leishmaniasis diagnosis, Appl Microbiol Biotechnol 2020;104(19):8105-16.

  63. De Vries HJC y Schallig HD, Cutaneous leishmaniasis: a 2022updated narrative review into diagnosis and management developments,Am J Clin Dermatol 2022; 23(6):823-40.

  64. Wanji S, Deribe K, Minich J, Debrah AY, Kalinga A, Kroidl I, LuguetA, Hoerauf A y Ritter M, Podoconiosis. From known tounknown: obstacles to tackle, Acta Trop 2021; 219:105918. doi:10.1016/j.actatropica.2021.105918. Epub: 9 de abril de 2021.pmid: 33839086.

  65. Davey G y Burridge E, Community-based control of a neglectedtropical disease: the mossy foot treatment and prevention association,plos Negl Trop Dis 2009; 3(5):e424. doi: 10.1371/journal.pntd.0000424. pmid: 19479039; pmcid: pmc: 2682702.




2020     |     www.medigraphic.com